Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

briefingcom Jan. 22 at 4:34 PM

$ABT: Abbott Labs (-7.8%) is sliding after a Q4 revenue miss and soft Q1 guidance overshadowed strength in Medical Devices and Diabetes Care. With sentiment already cautious after $JNJ, is near-term visibility the market’s biggest concern? Get all the details here: https://www.briefing.com/story-stocks/archive/2026/1/22/abbott-labs-catches-a-cold-q4-revenue-miss-and-cautious-guidance-chill-the-stock-(abt)?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link #Earnings #revenue #guidance #Healthcare #Stocks

0 · Reply

Deeznutsswapmeet Jan. 22 at 4:22 PM

$JNJ $KVUE My guy blocked me! Please make sure he is aware that whatever garbage he posted today is without question 100% wrong.

0 · Reply

Deeznutsswapmeet Jan. 22 at 4:18 PM

$JNJ Another fortune teller!! Great call on this post. You really nailed it.

0 · Reply

IN0V8 Jan. 22 at 3:41 PM

$JNJ BofA Global Research raises price objective to $221 from $220 Citigroup raises target price to $250 from $232 JP Morgan raises target price to $225 from $205 Leerink Partners raises target price to $232.00 from $201.00 Morgan Stanley raises target price to $200 from $197 Raymond James raises target price to $237 from $209 Scotiabank raises target price to $265 from $230 Stifel raises target price to $220 from $205 TD Cowen raises target price to $250 from $222

0 · Reply

SparkyReturns Jan. 22 at 3:39 PM

$PFE Here's an idea for biotech investors. Big Pharma should pay attention to this tiny company that is saving lives and creating value. Look at the incredible setup for Seastar (ICU). 8M MC, with a TAM in the Billions (read that again); 2M NET revenue this year expected; 90% margins; Ramping up a product which will potentially/likely become Standard of Care for a number of conditions involving hyper-inflammation and sepsis (AKI, Cardiorenal, burn victims, transplant patients); Saves lives of AKI patients and ELIMINATES dialysis dependency; Total addressable market anywhere from 2B-20B; Zero debt; Pivotal adult AKI study to be completed in 12-15 months, possibly sooner; Being used at Mayo Clinic, Cinci Childrens, CHOP (Philadelphia), many more; 6 Breakthrough Device Designations (most ever); Cash burn reducing due to ramped up pediatric sales for longer runway; So, 8M MC for a company that will be worth Billions in a few years. $JNJ $TAK $NVS $MRK

0 · Reply

brief1066 Jan. 22 at 2:10 PM

$JNJ nothing can make this go green and stay green

1 · Reply

Shorting_BTC_Since_2009 Jan. 22 at 2:10 PM

$IBRX just a tip. immunity BIO with 13 consecutive Green Day’s is on SSR today!!! $LLY $MRNA $SLS $JNJ

0 · Reply

Shorting_BTC_Since_2009 Jan. 22 at 2:07 PM

$IBRX will break 24,000 followers today.$SLS $LLY $JNJ $MRNA

1 · Reply

PickAlpha Jan. 22 at 2:06 PM

PickAlpha Morning Report | 2026-01-22 — 6 material moves and analysis • Goldman raises 2026 gold target 5 400 — $GLD, $GDX • Gold and silver spike on geopolitical tensions — $GLD, $SLV • JNJ beats Q4 and raises 2026 guidance — $JNJ, $XLV • Etc.. https://research.pickalpha.ai/p/pickalpha-morning-report-2026-01-a54

0 · Reply

PickAlpha Jan. 22 at 1:53 PM

PickAlpha Morning Report - Company News: 2026.01.22 News Analysis - 1/2: Johnson & Johnson posts strong Q4 2025 results, lifts 2026 sales and EPS outlook | View: A clear beat-and-raise quarter, mid-single-digit 2026 growth guidance, and visible oncology and MedTech catalysts… $JNJ $XLV $SPY

0 · Reply

Johnson & Johnson is doing 'great things for patients,' CFO says

Jan 21, 2026, 11:20 PM EST - 13 hours ago

Plaintiffs' Evidence Will Be Heard in Cases Alleging J&J's Talc Products Caused Women's Ovarian Cancer, Announced Levin Papantonio Attorney Chris Tisi

Jan 21, 2026, 6:45 PM EST - 18 hours ago

Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth

Jan 21, 2026, 1:56 PM EST - 23 hours ago

Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript

Jan 21, 2026, 12:15 PM EST - 1 day ago

Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates

Jan 21, 2026, 10:00 AM EST - 1 day ago

OKLO Upgrade Rally, ULTA Adds Bullish Momentum, JNJ Earnings

OKLO ULTA

Jan 21, 2026, 7:26 AM EST - 1 day ago

J&J expects to hit $100 billion in revenue next year after new strategy pays off

Jan 21, 2026, 6:23 AM EST - 1 day ago

Johnson & Johnson forecasts 2026 profit above Wall Street estimates

Jan 21, 2026, 6:20 AM EST - 1 day ago

J&J's Sales and Profit Rise on Strong Cancer and Autoimmune Drug Sales

Jan 21, 2026, 6:20 AM EST - 1 day ago

Johnson & Johnson reports Q4 and Full-Year 2025 results

Jan 21, 2026, 1:07 AM EST - 1 day ago

Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Jan 20, 2026, 8:37 AM EST - 2 days ago

How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings

Jan 19, 2026, 8:00 AM EST - 3 days ago

Is Johnson & Johnson A Dividend Stock, Or Something Else?

Jan 19, 2026, 5:08 AM EST - 3 days ago

Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)

$TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide$

Jan 14, 2026, 4:30 PM EST - 7 days ago

TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide

Jan 13, 2026, 8:00 AM EST - 9 days ago

Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting

Jan 13, 2026, 2:40 AM EST - 9 days ago

Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors

DHR GOOG LIN MSFT ORCL

Jan 12, 2026, 6:32 PM EST - 9 days ago

Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court

Jan 12, 2026, 2:06 PM EST - 9 days ago

Johnson & Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 7:40 AM EST - 11 days ago

The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips

AMGN CVX HD KO MRK NKE PG

Jan 10, 2026, 10:00 AM EST - 12 days ago

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Jan 10, 2026, 9:52 AM EST - 12 days ago

January Dogs Of The Dow: One Ideal 'Safer' Dividend Buy

AMGN CRM DIS HD HON KO MRK

Jan 9, 2026, 9:59 AM EST - 13 days ago

Cramer's Mad Dash: Johnson & Johnson

Jan 9, 2026, 5:10 AM EST - 13 days ago

Johnson & Johnson Strikes Deal With White House to Lower Drug Prices

Jan 8, 2026, 9:33 PM EST - 13 days ago

Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices

Jan 8, 2026, 8:43 PM EST - 13 days ago

Johnson & Johnson reaches deal with US government to lower drug prices

Jan 8, 2026, 8:24 PM EST - 13 days ago

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Jan 7, 2026, 8:00 AM EST - 15 days ago

Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration

Jan 6, 2026, 8:03 AM EST - 16 days ago

Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study

$Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma$

Jan 6, 2026, 6:52 AM EST - 16 days ago

Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma

Jan 2, 2026, 5:06 PM EST - 19 days ago

Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

AMGN CVX HD KO MRK NKE PG

Jan 2, 2026, 4:17 PM EST - 19 days ago

Dow Jones 2025 Scorecard: Caterpillar, Nvidia Help Index Hit All-Time Highs – Top 5 Winners & Losers

CAT NVDA GS IBM

Jan 2, 2026, 8:00 AM EST - 20 days ago

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

Dec 31, 2025, 8:47 AM EST - 22 days ago

Best Dividend Aristocrats For January 2026

ABBV ABT ADM ADP AFL ALB AMCR

Dec 30, 2025, 1:31 PM EST - 22 days ago

The Big 3: JNJ, SNDK, TWLO

TWLO SNDK

Dec 30, 2025, 9:55 AM EST - 23 days ago

Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now

Dec 30, 2025, 5:05 AM EST - 23 days ago

More Upside For JNJ Stock In 2026?

Dec 29, 2025, 1:56 PM EST - 23 days ago

Dogs of the Dow Had a Strong Year as Dividends Paid Off

HD IBM NKE UNH

Dec 29, 2025, 8:00 AM EST - 24 days ago

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

Dec 28, 2025, 6:44 AM EST - 25 days ago

Best Dividend Kings: December 2025

ABBV ABM ABT ADM ADP AWR BDX

Dec 26, 2025, 8:13 AM EST - 27 days ago

Johnson & Johnson halts mid-stage trial of experimental eczema drug

Dec 23, 2025, 11:41 AM EST - 4 weeks ago

J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling

Dec 23, 2025, 12:34 AM EST - 4 weeks ago

J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award

Dec 22, 2025, 11:15 PM EST - 4 weeks ago

Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder

Dec 20, 2025, 3:55 AM EST - 4 weeks ago

Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder

Dec 19, 2025, 5:54 PM EST - 4 weeks ago

Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson

Dec 18, 2025, 8:00 AM EST - 5 weeks ago

Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

Dec 18, 2025, 2:09 AM EST - 5 weeks ago

Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

Dec 17, 2025, 6:49 PM EST - 5 weeks ago

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

Dec 15, 2025, 6:22 PM EST - 5 weeks ago

Final Trade: JNJ, NVO, UBER, BMY

BMY NVO UBER

briefingcom Jan. 22 at 4:34 PM

0 · Reply

Deeznutsswapmeet Jan. 22 at 4:22 PM

$JNJ $KVUE My guy blocked me! Please make sure he is aware that whatever garbage he posted today is without question 100% wrong.

0 · Reply

Deeznutsswapmeet Jan. 22 at 4:18 PM

$JNJ Another fortune teller!! Great call on this post. You really nailed it.

0 · Reply

IN0V8 Jan. 22 at 3:41 PM

0 · Reply

SparkyReturns Jan. 22 at 3:39 PM

0 · Reply

brief1066 Jan. 22 at 2:10 PM

$JNJ nothing can make this go green and stay green

1 · Reply

Shorting_BTC_Since_2009 Jan. 22 at 2:10 PM

$IBRX just a tip. immunity BIO with 13 consecutive Green Day’s is on SSR today!!! $LLY $MRNA $SLS $JNJ

0 · Reply

Shorting_BTC_Since_2009 Jan. 22 at 2:07 PM

$IBRX will break 24,000 followers today.$SLS $LLY $JNJ $MRNA

1 · Reply

PickAlpha Jan. 22 at 2:06 PM

0 · Reply

PickAlpha Jan. 22 at 1:53 PM

0 · Reply

NeLoWtF_ Jan. 22 at 1:39 PM

$SLS The calm before the STORM. ⚡️ Pre-market just gave us a massive clue: a quick test of resistance saw us hitting $4.91 on tiny 120k volume. The path to $5+ is wide open and the "ask" is thin. Shorts are absolutely trapped and they know it. 🩳🔥 We are staring at the most anticipated IDMC PR of 2026. This isn't just another biotech play; this is a strategic asset grab. With $4.7B+ in TAM and GPS data that destroys the competition, the Institutional hunger is real. 🏛️💰 The 23rd January anniversary is tomorrow. The stage is set for the biggest Big Pharma BID WAR of the decade. $JNJ $MRK $BMY... who’s going to blink first? 20k shares locked in. Strong hands only. We don't sell for peanuts, we wait for the life-changing buyout. 💎🙌 #SLS #IDMC #GPS #Buyout #ShortSqueeze #BioTech

4 · Reply

Suite510 Jan. 22 at 1:13 PM

$JNJ $KVUE $SPX Will implode by March lol 😂 has expected In a statement from the Alabama-based Beasley Allen Law Firm, attorney Andy Birchfield took issue with J&J's characterization of the decision, saying the company should "reconsider its horribly flawed strategy." “This is a major victory for 67,000 women poisoned by talc and harmed again by Johnson & Johnson's pathological need to obstruct, delay and lie.

0 · Reply

viggizags Jan. 22 at 12:16 PM

$BTC.X for seriously, you guys should have just bought $JNJ coin. Now thats some performance. Ha

0 · Reply

QuantitativeTrading_ Jan. 22 at 11:55 AM

📊 Earnings Recap | Jan 21, 2026 $JNJ (Johnson & Johnson) reported: EPS: $2.46 vs Est. $2.43 ✅ Revenue: $24.56B vs Est. $24.16B ✅ Intraday Move: -0.09% Solid beats on both EPS and revenue, yet the stock barely moved — perhaps priced in or awaiting broader sector catalysts. Watching closely — follow-through and sector reaction could define near-term trend. If this helps, tap @QuantitativeTrading_

0 · Reply

Suite510 Jan. 22 at 4:12 AM

$JNJ $KVUE Oh boy ruff day at JNJ corporate 😂 “I find, by a preponderance of the evidence, that the Plaintiffs’ experts have applied reliable methodologies to arrive at their opinions that the pre- and post-2020 epidemiologic studies, taken as a whole, demonstrate a positive, statistically significant association between genital talc powder use and ovarian cancer,” Wolfson wrote.

0 · Reply

MoonBanditt Jan. 22 at 1:30 AM

Another high quality alert from @Strategistbrady 🔥A must-track for anyone focused on trading. $RR $JNJ $COST $NOW Best

0 · Reply

Suite510 Jan. 21 at 11:26 PM

$JNJ $KVUE Sure 2.2B for 22 plaintiffs that’s a verdict reduction right Your an idiot and now blocked, that’s why you have 3 followers you have Zero 0️⃣ knowledge = Zero 0️⃣ followers 😂 Next move for JNJ is a $30B settlement or $50B MDL verdict Cheers 🥂 👋

0 · Reply

Deeznutsswapmeet Jan. 21 at 11:09 PM

$JNJ $KVUE Now you’re running out of clickbait to post. Here’s where you keep missing, the most important part of every lawsuit is how much actually gets paid. A jury “awarding” a plaintiff in a corporate lawsuit is only for media to post fake stories that people like you fall for. Appeals courts are made up of judges who overturn these verdicts immediately because they know corporate law and juries don’t. That fantasy number a jury of people decided to award disappears like a fart in the wind.

0 · Reply

Suite510 Jan. 21 at 9:50 PM

$JNJ $KVUE It’s time for a 80’s throwback CNN News JULY 13, 2018 $4.69 billion verdict against Johnson & Johnson's talcum powder | CNN A US jury has ordered Johnson & Johnson to pay $4.69 billion to 22 women who alleged the powder caused their ovarian cancer. The largest verdict to date and the first to successfully argue talcum powder contains asbestos.

0 · Reply

HALOMOON Jan. 21 at 9:36 PM

YHGJ is Breaking out on fire! $RR $JNJ $COST $NOW

0 · Reply

HALOMOON Jan. 21 at 9:24 PM

$RR $IBRX $JNJ $COST here

0 · Reply

Deeznutsswapmeet Jan. 21 at 8:59 PM

$JNJ The number of idiots on here that see red pre market and think they know a thing about price action is astounding. None of you clowns have a clue about what you’re posting. Crossing your fingers and hoping you’re right is not a great strategy and shows how little you know.

0 · Reply

Market Cap	525.73B
Revenue (ttm)	88.82B
Net Income (ttm)	14.07B
EPS (ttm)	N/A
PE Ratio	21.07
Forward PE	19.08
Profit Margin	15.84%
Debt to Equity Ratio	0.50

Volume	5,934,812
Avg Vol	9,011,500
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	87%
Beta	0.34
Analysts	Strong Sell
Price Target	$212.88